Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2012

View Archived Issues

Genetic alterations linked to immune function dysregulation with cold urticaria

New hepatitis C virus NS5A inhibitor identified and characterized

Full results published of phase III breast cancer study CLEOPATRA

Researchers at Novartis present new insulin-like growth factor 1 receptor antagonists

U.S. team designs novel series of antibacterial agents

Ardea Biosciences discloses new inhibitors of urate transport

Novel agents for HIV infection synthesized in Korea

One-pot cascade synthesis yields modulators of centrosome integrity

New muscarinic acetylcholine M1 receptor positive allosteric modulators patented

Roche technology used to identify mutations underlying hearing loss

Idenix Pharmaceuticals provides update on agents for hepatitis C

Lunesta approved for Japanese market

Gilead Sciences completes acquisition

DARA BioSciences announces acquisitions

Medivation and Pfizer report data from phase III CONCERT trial

Ranmark approved in Japan

Takeda's Azilva approved in Japan

Niiki Pharma completes first-in-human trial of anticancer agent

Pevion reports encouraging data on PEV-7 for recurrent vulvovaginal candidiasis

FDA approves new product for methotrexate poisoning due to impaired renal function

Abilify approved for new indication in Japan

OxiFast approved in Japan for cancer pain

Xarelto approved in Japan for prevention of stroke and systemic embolism in patients with AF

Phase II tivantinib study in second-line hepatocellular carcinoma meets primary endpoint

Regnite approved in Japan for restless legs syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...